Zymeworks Inc. (ZYME) SEC Filings & Earnings Calls

Transaction subject to HSR Act waiting period and regulatory approvals

“Transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976” · word for word

Integration risk and potential failure to realize anticipated benefits of the acquisition.

“Risks related to the financing in connection with the closing of the acquisition; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period.”

Dependence on partner Jazz for commercialization; royalty revenue subject to sales performance.

“Royalties are tiered 10-20% on Jazz's net sales; commercial success depends on Jazz's execution.”

Lack of profitability

“We have incurred significant losses since our inception. Our net losses for the years ended December 31, 2025 and 2024 were $81.1 million and $122.7 million, respectively, while our net loss for the six months ended June 30, 2026 was $45.0 million.” · word for word

Dependence on third-party manufacturers

“We rely on third-party manufacturers to produce our product candidates and on other third parties to provide supplies and store, monitor and transport bulk drug substance and drug product.” · word for word

Intellectual property challenges

“Our success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.” · word for word

Need for additional capital

“We may require additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.” · word for word

Regulatory risk for zanidatamab approval; PDUFA date in August 2026

“August 25, 2026 U.S. PDUFA target action date for zanidatamab” · word for word

Acquisition integration risk for Theravance Biopharma

“Acquisition of Theravance Biopharma, Inc. expected to close in 2H 2026” · word for word

Termination fee of $32.5M if deal breaks under certain conditions.

“Company will be required to pay Parent a termination fee of $32,515,000 in specified circumstances.”

Forward-looking statements subject to risks; milestone payments not guaranteed.

“These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially”

Dependence on Partner Milestones

“Our revenue consists of collaboration revenue, including amounts recognized relating to upfront non-refundable payments for licenses or options to obtain future licenses, research and development funding, milestone payments and royalties earned under collaboration and license agreements.” · word for word

Clinical Trial Failure Risk

“The outcome of clinical trials is inherently uncertain, and current and planned clinical trials may not satisfy the requirements of the FDA or comparable regulatory authorities outside the United States.” · word for word

Royalty Monetization Indebtedness

“The terms of our loan agreement impose certain restrictions on our activities, and failure by us or our subsidiaries to fulfill applicable obligations under the loan agreement may cause the repayment obligations to accelerate.” · word for word

Competition

“We face significant competition, and if any competitors develop and market products that are more effective, safer and/or less expensive than our product candidates, our ability to generate revenue will be negatively impacted.” · word for word

Regulatory Approval Uncertainty

“If our partnered product candidates do not meet regulatory and commercial milestones, or experience significant delays in doing so, our results of operations will be materially adversely affected.” · word for word

Regulatory approval risk for zanidatamab; PDUFA date set but outcome uncertain.

“PDUFA target action date of August 25, 2026; approval not guaranteed.” · word for word

Clinical trial risk for ZW191; Phase 1 data promising but early stage.

“ZW191 Phase 1 data in PROC; Part 2 fully enrolled but ongoing.”

Management transition risk; potential for strategic shifts or disruption.

“Executive appointment without further context.”

Dependence on partner Jazz for Ziihera regulatory and commercial success.

“Supplemental Biologics License Application for Ziihera to be completed by our partner Jazz.”

Net loss still significant despite improvement.

“Net loss of $81.1 million in 2025.”

Repayment depends on Ziihera commercial success; if sales disappoint, royalty stream may be insufficient.

“Repayment secured by 30% of Ziihera royalties; Ziihera is still in early commercial stage with accelerated approval for BTC.”

Note has repayment cap (1.65x by 2033, 1.925x thereafter); if Ziihera is highly successful, effective cost of capital could be high.

“Press release: 'cumulative payments of either 1.65x the note amount by December 31, 2033, or 1.925x the note amount at any time thereafter'”

Dependence on partnership milestones and royalties for revenue

“It is possible, however, that our strategic partners’ programs will not advance as currently contemplated, which would negatively affect the amount of development and commercial milestone payments and royalties on potential future product sales we may receive.” · word for word

Clinical development risk for pipeline candidates

“We intend to advance our other ongoing ADC research programs, including potential clinical development of ZW220, ZW327, and ZW418 ... only if and when partnerships, collaborations, and/or other sources of external funding become available.”

Royalty Pharma loan repayment obligation

“Under the terms of the Loan Agreement, the amount payable to the lenders no later than the Maturity Date is approximately $481.3 million, provided that if the Loan is repaid in full on or before December 31, 2033, the amount payable to the lenders is $412.5 million.” · word for word

Dependence on regulatory approvals for milestone payments

“Milestone payments are contingent on regulatory approvals of Ziihera in multiple jurisdictions.”

Dependence on regulatory approvals for milestone payments; execution risk of new strategy.

“Potential near-term milestone payments upon successful global regulatory approvals of Ziihera in GEA.” · word for word

Clinical-stage biotech risk

“Zymeworks is a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics” · word for word

Reliance on partnerships

“Our partner, Jazz Pharmaceuticals, obtained from the FDA accelerated approval of Ziihera” · word for word

Governance/regulatory risk (AMF fine)

“On December 13, 2024, the Enforcement Committee of the Autorité des Marchés Financiers (AMF) fined Mr. Nodelman and EcoR1 Capital LLC €3.0 million and €7.0 million, respectively” · word for word

Clinical-stage biotech with no approved products; revenue dependent on partnerships and milestones.

“Clinical-stage biotechnology company... partnership-based model”

Cash burn rate; $299.4M provides runway into 2H-2027, but future funding may be needed.

“Cash resources of $299.4 million... provides a projected cash runway into 2H-2027”

Dependence on collaboration milestones for revenue

“Revenue is primarily from R&D collaborations and milestone payments, which are lumpy and dependent on partner decisions.”

History of losses and need for additional funding

“The Company has a history of significant losses since inception and may require substantial additional funding.”